Cogent Biosciences, Inc. (NASDAQ:COGT) NDA Accepted for AdvSM; PDUFA Set for June 29, 2027
Cogent Biosciences, Inc. said the FDA accepted its NDA for bezuclastinib in Advanced Systemic Mastocytosis and set a PDUFA action date of June 29, 2027. FDA does not plan an advisory committee and noted no potential review issues.Material DetailsContext by AI AnalystThis advances a multi-indication…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.